Trials / Completed
CompletedNCT01009814
Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1
Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following 8 days of therapy in at least one dosing regimen that is safe and well tolerated in Clade B HIV-1 infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-663068 | BMS-663068 will be administered as a tablet formulation |
| DRUG | Ritonavir | Ritonavir will be administered as a capsule. |
Timeline
- Start date
- 2009-11-23
- Primary completion
- 2010-06-25
- Completion
- 2010-06-25
- First posted
- 2009-11-09
- Last updated
- 2020-01-03
- Results posted
- 2020-01-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01009814. Inclusion in this directory is not an endorsement.